Abstract
Restenosis, the re-narrowing of a blood vessel after removal of atherosclerotic plaque, is a major limitation of surgical treatments for atherosclerosis. Various attempts to prevent or treat restenosis by pharmacological or mechanical approaches have had limited success in clinical trials. Hence, there is wide interest in developing new strategies to prevent or treat restenosis. This review discusses ‘a new-generation therapy’ that uses functional nanoparticles to effectively deliver active drug molecules. The potential platforms for nanoparticle-based solutions to restenosis include organic (e.g. polymers, liposomes, and proteins) and inorganic nanoparticles (e.g. layered double hydroxides, titanium oxide nanotubes, and magnetic nanoparticles,). Many in vitro and in vivo studies based on these platforms demonstrate the feasibility and potential of using nanoparticle drug delivery systems for preventing or treating restenosis, but as yet few have reached clinical trials. It is suggested that using inorganic nanoparticles to target deliver multi-functional drugs will be a promising approach to preventing or treating restenosis.
Keywords: Restenosis, nanoparticle, drug delivery, layered double hydroxide.
Current Pharmaceutical Design
Title:Restenosis Treatments Using Nanoparticle-based Drug Delivery Systems
Volume: 19 Issue: 35
Author(s): Zi Gu, Barbara E. Rolfe, Anita C. Thomas and Zhi Ping Xu
Affiliation:
Keywords: Restenosis, nanoparticle, drug delivery, layered double hydroxide.
Abstract: Restenosis, the re-narrowing of a blood vessel after removal of atherosclerotic plaque, is a major limitation of surgical treatments for atherosclerosis. Various attempts to prevent or treat restenosis by pharmacological or mechanical approaches have had limited success in clinical trials. Hence, there is wide interest in developing new strategies to prevent or treat restenosis. This review discusses ‘a new-generation therapy’ that uses functional nanoparticles to effectively deliver active drug molecules. The potential platforms for nanoparticle-based solutions to restenosis include organic (e.g. polymers, liposomes, and proteins) and inorganic nanoparticles (e.g. layered double hydroxides, titanium oxide nanotubes, and magnetic nanoparticles,). Many in vitro and in vivo studies based on these platforms demonstrate the feasibility and potential of using nanoparticle drug delivery systems for preventing or treating restenosis, but as yet few have reached clinical trials. It is suggested that using inorganic nanoparticles to target deliver multi-functional drugs will be a promising approach to preventing or treating restenosis.
Export Options
About this article
Cite this article as:
Gu Zi, Rolfe E. Barbara, Thomas C. Anita and Xu Ping Zhi, Restenosis Treatments Using Nanoparticle-based Drug Delivery Systems, Current Pharmaceutical Design 2013; 19 (35) . https://dx.doi.org/10.2174/1381612811319350009
DOI https://dx.doi.org/10.2174/1381612811319350009 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anesthetic Cardioprotection in Clinical Practice From Proof-of-Concept to Clinical Applications
Current Pharmaceutical Design Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug
Current Diabetes Reviews Structural Neuroimaging Findings in Major Depressive Disorder Throughout Aging: A Critical Systematic Review of Prospective Studies
CNS & Neurological Disorders - Drug Targets Role of Statins in Diabetes Complications
Current Diabetes Reviews Administration of Drug and Nutritional Components in Nano-Engineered Form to Increase Delivery Ratio and Reduce Current Inefficient Practice
Recent Patents on Drug Delivery & Formulation Mitochondrial Aldehyde Dehydrogenase, A Potential Drug Target for Protection of Heart and Brain from Ischemia/Reperfusion Injury
Current Drug Targets Telmisartan Blocks Advanced Glycation End Product (AGE)-Induced Plasminogen Activator Inhibitor-1 (PAI-1) Gene Expression in Endothelial Cells via Activation of Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ )
Letters in Drug Design & Discovery Selenium and Autoimmune Diseases: A Review Article
Current Rheumatology Reviews Immunotoxicity and Immunogenicity of Biopharmaceuticals: Design Concepts and Safety Assessment
Current Drug Safety Lithium and its Neuroprotective and Neurotrophic Effects: Potential Treatment for Post-Ischemic Stroke Sequelae
Current Drug Targets Chymase Inhibitor As a Novel Therapeutic Strategy for Anti-Vascular Remodeling
Vascular Disease Prevention (Discontinued) Expression and Function of the Leukocyte Integrins in Medicine
Current Genomics Nitric Oxide as a Marker for Levo-Thyroxine Therapy in Subclinical Hypothyroid Patients
Current Vascular Pharmacology Genetic Variations and Subclinical Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus
Current Vascular Pharmacology p38 Mitogen-Activated Protein Kinase: A Critical Node Linking Insulin Resistance and Cardiovascular Diseases in Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Safety Aspects of Statins: Which Factors Create the Adverse Effects of Statins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Safety and Efficacy of Aliskiren in the Treatment of Hypertension and Associated Clinical Conditions
Current Drug Safety Role of ERK1/2 Activation In Thrombin-Induced Vascular Smooth Muscle Cell Hypertrophy
Current Hypertension Reviews Osteoprotegerin in Cardiovascular Disease: Ally or Enemy?
Current Pharmaceutical Design Advantages of Structure-Based Drug Design Approaches in Neurological Disorders
Current Neuropharmacology